Clinical trial
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750 is registered in ClinicalTrials.gov with PMV Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Lead sponsor
- PMV Pharmaceuticals, Inc
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- October 29, 2020
- Completion date
- December 31, 2027
- Enrollment
- 300 (estimated)
- Sites
- 76
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant neoplasm, advanced solid tumor, breast cancer, colorectal cancer, endometrial cancer, er/pr positive breast cancer, er/pr(+), her2(-) breast cancer, gall bladder cancer, head and neck cancer, her2+ breast cancer, her2- breast cancer, her2-negative breast cancer, her2-positive breast cancer, locally advanced, lung cancer, metastatic cancer, metastatic solid tumor, non-small cell lung cancer, non-small cell lung carcinoma, nsclc, nsclc (non-small cell lung cancer), other cancer, ovarian cancer, prostate cancer, sclc, small cell lung cancer, small cell lung cancer ( sclc ), small cell lung carcinoma, tnbc, triple negative breast cancer